Literature DB >> 23108051

Cdk1 interplays with Oct4 to repress differentiation of embryonic stem cells into trophectoderm.

Lei Li1, Juanjuan Wang, Jie Hou, Zhaojia Wu, Yuan Zhuang, Mengxue Lu, Yiran Zhang, Xiaohan Zhou, Zhaoyan Li, Wei Xiao, Weiwei Zhang.   

Abstract

Cdk1 plays an important role in undifferentiated ES cells, but the underlying mechanism remains unclear. This study explores how Cdk1 collaborates with Oct4 to inhibit differentiation in mouse ES cells. We show a direct interaction between Cdk1 and Oct4, whereas other Cdk members, including Cdk2 and Cdk4, fail to associate with Oct4. By immunocytochemistry we show that Cdk1 and Oct4 co-localize in ES cells. The biological function of the Cdk1-Oct4 complex was also addressed. We found that Cdk1 enhances the binding of Oct4 on the trophectoderm marker Cdx2 and promotes Cdx2 repression. This regulation is independent of Cyclins and of the kinase activity of Cdk1. Our study explains how Cdk1 and Oct4 interplay to inhibit ES cell differentiation into trophectoderm and thereby maintain stemness. Crown
Copyright © 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108051     DOI: 10.1016/j.febslet.2012.10.030

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  A nontranscriptional role for Oct4 in the regulation of mitotic entry.

Authors:  Rui Zhao; Richard W Deibler; Paul H Lerou; Andrea Ballabeni; Garrett C Heffner; Patrick Cahan; Juli J Unternaehrer; Marc W Kirschner; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-16       Impact factor: 11.205

Review 2.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

Review 3.  G1-phase progression in pluripotent stem cells.

Authors:  Menno Ter Huurne; Hendrik G Stunnenberg
Journal:  Cell Mol Life Sci       Date:  2021-04-21       Impact factor: 9.261

Review 4.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

5.  CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells.

Authors:  I Neganova; K Tilgner; A Buskin; I Paraskevopoulou; S P Atkinson; D Peberdy; J F Passos; M Lako
Journal:  Cell Death Dis       Date:  2014-11-06       Impact factor: 8.469

6.  The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotency.

Authors:  Maheswara Reddy Emani; Elisa Närvä; Aki Stubb; Deepankar Chakroborty; Miro Viitala; Anne Rokka; Nelly Rahkonen; Robert Moulder; Konstantin Denessiouk; Ras Trokovic; Riikka Lund; Laura L Elo; Riitta Lahesmaa
Journal:  Stem Cell Reports       Date:  2015-02-19       Impact factor: 7.765

7.  CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency.

Authors:  Xiao Qi Wang; Chung Mau Lo; Lin Chen; Elly S-W Ngan; Aimin Xu; Randy Yc Poon
Journal:  Cell Death Differ       Date:  2016-09-16       Impact factor: 15.828

8.  Analysis of long noncoding RNA and mRNA using RNA sequencing during the differentiation of intramuscular preadipocytes in chicken.

Authors:  Tao Zhang; Xiangqian Zhang; Kunpeng Han; Genxi Zhang; Jinyu Wang; Kaizhou Xie; Qian Xue; Xiaomei Fan
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

Review 9.  Targeting cell cycle regulators in hematologic malignancies.

Authors:  Eiman Aleem; Robert J Arceci
Journal:  Front Cell Dev Biol       Date:  2015-04-09

Review 10.  Cell cycle and pluripotency: Convergence on octamer‑binding transcription factor 4 (Review).

Authors:  Shiqi She; Qucheng Wei; Bo Kang; Ying-Jie Wang
Journal:  Mol Med Rep       Date:  2017-09-13       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.